Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PCSK9 inhibitors: clinical evidence and implementation
Marc S. Sabatine
Nature Reviews Cardiology (2018) Vol. 16, Iss. 3, pp. 155-165
Closed Access | Times Cited: 300

Showing 1-25 of 300 citing articles:

A Modern Approach to Dyslipidemia
Amanda J. Berberich, Robert A. Hegele
Endocrine Reviews (2021) Vol. 43, Iss. 4, pp. 611-653
Open Access | Times Cited: 291
Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction
Paolo Severino, Andrea D’Amato, Mariateresa Pucci, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8118-8118
Open Access | Times Cited: 256
Regulation of glucose and lipid metabolism in health and disease
Ligong Chen, Xiaowei Chen, Xun Huang, et al.
Science China Life Sciences (2019) Vol. 62, Iss. 11, pp. 1420-1458
Closed Access | Times Cited: 227
Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis
Gregory Livshits, Alexander Kalinkovich
Ageing Research Reviews (2019) Vol. 56, pp. 100980-100980
Closed Access | Times Cited: 175
Multifunctional nanoparticle-mediated combining therapy for human diseases
Xiaotong Li, Xiuju Peng, Makhloufi Zoulikha, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 130
Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study
Wuqing Huang, Jun Xiao, Jianguang Ji, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 126
Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function
Daniel B. Rosoff, Andrew S. Bell, Jeesun Jung, et al.
Journal of the American College of Cardiology (2022) Vol. 80, Iss. 7, pp. 653-662
Open Access | Times Cited: 82
A mechanistic framework for cardiometabolic and coronary artery diseases
Simon Koplev, Marcus M. Seldin, Katyayani Sukhavasi, et al.
Nature Cardiovascular Research (2022) Vol. 1, Iss. 1, pp. 85-100
Open Access | Times Cited: 81
Small interfering RNA: Discovery, pharmacology and clinical development—An introductory review
Priyanga Ranasinghe, Melisande Addison, James W. Dear, et al.
British Journal of Pharmacology (2022) Vol. 180, Iss. 21, pp. 2697-2720
Open Access | Times Cited: 75
Durable and efficient gene silencing in vivo by hit-and-run epigenome editing
Martino Alfredo Cappelluti, Valeria Mollica Poeta, Sara Valsoni, et al.
Nature (2024) Vol. 627, Iss. 8003, pp. 416-423
Open Access | Times Cited: 70
SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells
Nunzia D’Onofrio, Francesco Prattichizzo, Raffaele Marfella, et al.
Theranostics (2023) Vol. 13, Iss. 2, pp. 531-542
Open Access | Times Cited: 54
Effects of shear stress on vascular endothelial functions in atherosclerosis and potential therapeutic approaches
Hongxin Cheng, Wen Zhong, Lu Wang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 158, pp. 114198-114198
Open Access | Times Cited: 51
Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics
Mei Jin, Jian Fang, Jiaojiao Wang, et al.
Acta Pharmacologica Sinica (2023) Vol. 44, Iss. 12, pp. 2358-2375
Closed Access | Times Cited: 44
A gut-derived hormone regulates cholesterol metabolism
Xiaoli Hu, Fengyi Chen, Liangjie Jia, et al.
Cell (2024) Vol. 187, Iss. 7, pp. 1685-1700.e18
Closed Access | Times Cited: 33
Regulatory mechanism of Reelin activity: a platform for exploiting Reelin as a therapeutic agent
Mitsuharu Hattori
Frontiers in Molecular Neuroscience (2025) Vol. 18
Open Access | Times Cited: 2
Unique roles of rare variants in the genetics of complex diseases in humans
Yukihide Momozawa, Keijiro Mizukami
Journal of Human Genetics (2020) Vol. 66, Iss. 1, pp. 11-23
Open Access | Times Cited: 130
An oral antisense oligonucleotide for PCSK9 inhibition
Peter Gennemark, Katrin Walter, Niclas Clemmensen, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 593
Closed Access | Times Cited: 101
Cryo-EM structures of NPC1L1 reveal mechanisms of cholesterol transport and ezetimibe inhibition
Ching-Shin Huang, Xinchao Yu, Preston Fordstrom, et al.
Science Advances (2020) Vol. 6, Iss. 25
Open Access | Times Cited: 79
Araloside C attenuates atherosclerosis by modulating macrophage polarization via Sirt1-mediated autophagy
Yun Luo, Shan Lu, Ye Gao, et al.
Aging (2020) Vol. 12, Iss. 2, pp. 1704-1724
Open Access | Times Cited: 74
Nucleic Acid Drugs—Current Status, Issues, and Expectations for Exosomes
Yoji Yamada
Cancers (2021) Vol. 13, Iss. 19, pp. 5002-5002
Open Access | Times Cited: 68
Pharmacological Effects and Molecular Protective Mechanisms of Astragalus Polysaccharides on Nonalcoholic Fatty Liver Disease
Jing Zhang, Quansheng Feng
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 48
The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer
Chi Chun Wong, Jian‐Lin Wu, Fenfen Ji, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Rare penetrant mutations confer severe risk of common diseases
Petko Fiziev, Jeremy F. McRae, Jacob C. Ulirsch, et al.
Science (2023) Vol. 380, Iss. 6648
Open Access | Times Cited: 38
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque
Raffaele Marfella, Francesco Prattichizzo, Celestino Sardu, et al.
Atherosclerosis (2023) Vol. 378, pp. 117180-117180
Closed Access | Times Cited: 38
Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study
Si Fang, James Yarmolinsky, Dipender Gill, et al.
PLoS Medicine (2023) Vol. 20, Iss. 1, pp. e1003988-e1003988
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top